High Growth Tech Stocks Leading The US Market

Over the last 7 days, the United States market has dropped 1.9%, yet over the longer term, it has risen by 14% in the last year with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term performance and promising long-term growth, identifying high growth tech stocks that demonstrate strong innovation and adaptability can be crucial for investors looking to capitalize on emerging opportunities within the US market.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	25.26%	29.10%	★★★★★★
TG Therapeutics	26.19%	37.78%	★★★★★★
Alkami Technology	21.95%	85.17%	★★★★★★
Travere Therapeutics	28.43%	65.01%	★★★★★★
AVITA Medical	27.78%	55.33%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	22.90%	58.64%	★★★★★★
Alvotech	31.17%	100.18%	★★★★★★
Zai Lab	28.33%	68.55%	★★★★★★
Lumentum Holdings	21.24%	119.37%	★★★★★★

Click here to see the full list of 239 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Organogenesis Holdings (NasdaqCM:ORGO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care, surgical, and sports medicine markets in the United States with a market cap of $639.21 million.

Operations: The company generates revenue primarily from its regenerative medicine segment, with reported earnings of $482.04 million.

Organogenesis Holdings, transitioning towards profitability, has demonstrated a robust annual earnings growth forecast at 71.83%, signaling potential in an otherwise challenging biotech sector. With a recent surge in quarterly sales to $126.66 million from $99.65 million the previous year and a shift from a net loss to a net income of $7.67 million, the company's financial health appears to be strengthening. Despite its current unprofitability and highly volatile share price, Organogenesis is expected to outpace the US market with an anticipated revenue growth of 9.2% annually compared to the market's 8.5%. This performance is underpinned by significant R&D investments aimed at driving future innovations and maintaining competitive edge in regenerative medicine—a field poised for substantial growth given aging populations and advanced treatment technologies.

• Click to explore a detailed breakdown of our findings in Organogenesis Holdings' health report.

• Understand Organogenesis Holdings' track record by examining our Past report.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Simply Wall St Growth Rating: ★★★★★★

Overview: Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics utilizing ribonucleic acid interference technology and has a market cap of approximately $31.45 billion.

Operations: Alnylam Pharmaceuticals generates revenue primarily through the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.25 billion. The company's financial performance is closely tied to its innovative approach in leveraging ribonucleic acid interference technology for therapeutic solutions.

Alnylam Pharmaceuticals, showcasing a robust trajectory in the biotech sector, reported a significant revenue jump to $2.25 billion in 2024, up from $1.83 billion the previous year. This growth is underpinned by its aggressive R&D strategy, which saw expenses of $593 million last year alone, aimed at pioneering RNAi therapeutics across various tissues. The firm's recent advancements include promising updates on nucresiran and partnerships like that with Regeneron for ALN-HTT02 targeting Huntington's disease. With Dr. Phillip Sharp’s transition to the Scientific Advisory Board after his retirement from the board of directors, Alnylam continues to leverage deep scientific expertise to drive innovation and address unmet medical needs in novel therapeutic areas.

• Get an in-depth perspective on Alnylam Pharmaceuticals' performance by reading our health report here.

• Review our historical performance report to gain insights into Alnylam Pharmaceuticals''s past performance.

Nutanix (NasdaqGS:NTNX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Nutanix, Inc. is a company that offers an enterprise cloud platform across various regions including North America, Europe, the Asia Pacific, the Middle East, Latin America, and Africa with a market capitalization of approximately $20.65 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, totaling approximately $2.32 billion.

Nutanix has demonstrated a robust performance with its recent earnings, marking a significant year-over-year revenue increase to $654.72 million in Q2 2025, up from $565.23 million. This growth is complemented by an impressive surge in net income to $56.43 million from $32.8 million, reflecting strong operational efficiency and market demand for its cloud services solutions. The company's forward-looking statements suggest continued expansion with projected full-year revenues reaching up to $2.515 billion, indicating confidence in sustained growth and innovation in the tech sector amidst evolving digital transformations. In addition to financial achievements, Nutanix's strategic movements include entering into a substantial credit agreement aimed at bolstering their working capital and supporting general corporate activities, ensuring they remain agile in a competitive landscape marked by rapid technological advancements and shifting enterprise needs towards hybrid multicloud environments. This approach not only underscores their commitment to scaling operations efficiently but also highlights their proactive stance on leveraging financial structures to maintain momentum within the high-growth tech arena.

• Click here and access our complete health analysis report to understand the dynamics of Nutanix.

• Examine Nutanix's past performance report to understand how it has performed in the past.

Where To Now?

• Delve into our full catalog of 239 US High Growth Tech and AI Stocks here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com